MedAdvisor Limited’s Shares Mounted On ASX After Announcing A Joint Venture With Zuellig Pharma

December 03, 2018 05:02 PM AEDT | By Team Kalkine Media

Google News:

MedAdvisor Limited’s Shares Mounted On ASX After Announcing A Joint Venture With Zuellig Pharma

Recent News

Oil in biggest gain since 2022 as Israel hits Iran, but Citi warns gai...

AEG Celebrates the LGBTQIA + Community at the 2025 LA Pride Parade

What happens if AI can do everything better than humans?

Brookfield Infrastructure reportedly acquiring Hotwire for $7 billion

On 3 November 2018, MedAdvisor Limited (ASX:MDR) announced that it has signed a Heads of Agreement to form a Joint Venture with Zuellig Pharma Holdings Pte Ltd. Following the release of this news, the share price of the company increased by 18.182 percent as on 3 December 2018.

Zuellig Pharma Holdings is one of the largest healthcare services groups in Asia, and it is having a business of US$12 billion which provides healthcare services to more than 350k medical facilities across Asia and works with more than 1,000 corporate clients which includes top 10 pharmaceutical companies in the world.

As per the Joint Venture agreement, MedAdvisor will form a 50:50 joint venture with Zuellig Pharma which will be based in Singapore to commercialize MedAdvisorâs medication management platform in Asia. MedAdvisor is planning to license its core intellectual property to the Joint Venture on an exclusive, royalty-free basis. Further, it will also develop localized versions of its platform for pharmacies and patients in the Filipino and South Korean markets. Both the companies have conducted in-depth product-market fit assessments, and they are sure that that MedAdvisorâs technology can be successfully rolled out in these countries, which share a similar prescription model as Australia.

Â As per MedAdvisorâs CEO, this Joint Venture is the most significant development in MedAdvisorâs history as Zuellig Pharma is the perfect partner to take the companyâs offerings into the region. The management of the company is excited that its global product platform which it is developing for the US and UK, will work just as well in Asia.

According to the CEO of Zuellig Pharma Mr. John Davison, the platform of MedAdvisor is having a potential to help millions of people manage their medications safely and effectively.Â This Joint Venture will increase the Zuellig Pharmaâs growing suite of digital solutions that address key pain points in delivering quality healthcare.

Zuellig Pharma is planning to market the Joint Ventureâs offering to its extensive network of pharmacies, medical clinics, and pharmaceutical manufacturers, initially focusing on the Philippines and South Korea in FY 2020, followed by launches in additional Asian markets. As per the companyâs announcement, this Joint Venture will generate multiple streams of revenue including software as a service subscription fees from pharmacies, transaction-based revenue and program fees from pharmaceutical manufacturers for the delivery of digital patient engagement programs.

In the last six months, the share price of the company decreased by 23.26 percent as on 30 November 2018. MDRâs shares traded at 0.039 with a market capitalization of circa $43.99 million as on 3 December 2018 (AEST 4:00 PM).

Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.